Bucladesine
From Wikipedia, the free encyclopedia
 |
|
|
Bucladesine
|
|
| Systematic (IUPAC) name | |
| sodium [(1R,2R,4R,5R)-2-[6-(butanoylamino)purin- 9-yl]-7-oxido-7-oxo-3,6,8-trioxa-7λ5- phosphabicyclo[3.3.0]oct-4-yl]methyl butanoate |
|
| Identifiers | |
| CAS number | 362-74-3 |
| ATC code | C01CE04 |
| PubChem | 28177 |
| Chemical data | |
| Formula | C18H23N5O8PNa |
| Mol. weight | 491.368 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Bucladesine is a phosphodiesterase inhibitor.
| Selective Phosphodiesterase inhibitors (C01CE, G04BE)edit | ||
|---|---|---|
| PDE1: | ||
| PDE2: | ||
| PDE3: | ||
| PDE4: | ||
| PDE5: | ||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
